PMID- 17009989
OWN - NLM
STAT- MEDLINE
DCOM- 20061109
LR  - 20181030
IS  - 1048-891X (Print)
IS  - 1048-891X (Linking)
VI  - 16
IP  - 5
DP  - 2006 Sep-Oct
TI  - HER-2/neu overexpression in uterine papillary serous cancers and its possible 
      therapeutic implications.
PG  - 1897-902
AB  - Uterine papillary serous carcinoma (UPSC) is a highly aggressive variant of 
      endometrial cancer with features similar to high-grade ovarian cancer. Patients 
      tend to be elderly, thin, have a high grade tumor with extensive extrauterine 
      disease at the time of diagnosis. The transmembrane receptor encoded by the HER-2 
      cellular oncogene is amplified in several types of human carcinomas and provides 
      an attractive therapeutic target. HER-2/neu, the transmembrane receptor encoded 
      by the c-erbB2 gene, is overexpressed by immunohistochemistry in <25% of ovarian 
      cancers and 20-30% of breast cancers, and <10% of endometrial cancer. There are 
      prognostic and therapeutic implications associated with the overexpression of 
      this transmembrane protein. Herceptin, a humanized murine monoclonal antibody 
      directed against the extracellular domain of the HER-2/neu protein, is being used 
      to treat breast cancer that overexpresses HER-2/neu. We reviewed all patients 
      diagnosed with UPSC between 1999-2001. Twenty-six patients were identified, and 
      19 patients had specimens available for evaluation. We performed 
      immunohistochemical analysis (Herceptest, Dako, Carpinteria, CA) on 19 paraffin 
      embedded blocks of UPSC tumors looking for HER-2/neu over expression. Five out of 
      19 (26%) stained heavily (3+) for HER-2/neu receptor protein. Four of these five 
      patients had advanced disease at diagnosis. Two of these patients were 
      subsequently treated with Herceptin; one with complete response and one with 
      stable disease based on CT scan and CA-125 findings. Targeting HER-2/neu may be 
      beneficial for a select group of patients with UPSC. We are continuing to 
      evaluate samples for HER-2/neu over expression by fluorescence in situ 
      hybridization (FISH).
FAU - Villella, J A
AU  - Villella JA
AD  - Department of Surgery, Division of Gynecologic Oncology, Roswell Park Cancer 
      Institute, Buffalo, New York 14263, USA. jvillella@ligynonc.com
FAU - Cohen, S
AU  - Cohen S
FAU - Smith, D H
AU  - Smith DH
FAU - Hibshoosh, H
AU  - Hibshoosh H
FAU - Hershman, D
AU  - Hershman D
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - Int J Gynecol Cancer
JT  - International journal of gynecological cancer : official journal of the 
      International Gynecological Cancer Society
JID - 9111626
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Agents/therapeutic use
MH  - Cystadenocarcinoma, Serous/drug therapy/*metabolism
MH  - Endometrial Neoplasms/drug therapy/*metabolism
MH  - Female
MH  - Gene Amplification
MH  - Gene Expression Regulation, Neoplastic
MH  - Genes, erbB-2
MH  - Humans
MH  - Receptor, ErbB-2/genetics/*metabolism
MH  - Trastuzumab
EDAT- 2006/10/03 09:00
MHDA- 2006/11/11 09:00
CRDT- 2006/10/03 09:00
PHST- 2006/10/03 09:00 [pubmed]
PHST- 2006/11/11 09:00 [medline]
PHST- 2006/10/03 09:00 [entrez]
AID - IJG664 [pii]
AID - 10.1111/j.1525-1438.2006.00664.x [doi]
PST - ppublish
SO  - Int J Gynecol Cancer. 2006 Sep-Oct;16(5):1897-902. doi: 
      10.1111/j.1525-1438.2006.00664.x.